

- **Name:** MATTHEW YOUNG
  - **Current Position & Affiliation:** Dr H Bliss Murphy Murphy Cancer Center NL  
Health Services St. John's, NL, Canada
  - **Country:** UK
- 

• **Educational Background:**

- SEP 2009-JUN 2013

Bachelor of Science (Honours) Memorial University, Newfoundland

- AUG2013-MAY2017

Doctor of Medicine (MD) Memorial University, Newfoundland

- JUL2017-JUN2022

Medical Oncology Residency McGill University Chief Medical Oncology Resident (2021-2022)

- NOV2022-AUG2024

Genitoruinary Clinical Trials Fellow Queen Mary University London / Barts Cancer Institute  
Supervised by Professor Thomas Powles Delegated Sub-Investigator on 20+ phase I-III clinical trials  
Research component included guideline creation, manuscript preparation and participation in local and international congresses

- OCT2024-

Medical Oncologist (Consultant Physician) Cancer Care Program, NL Health Services Genitourinary  
Site Lead Responsible for the treatment of Genitourinary (Prostate, Germ Cell, Bladder and Renal)  
cancers, breast cancers and melanoma, including inpatient and outpatient patient management

• **Professional Experience:**

AUG 2024 - Fellow of the Royal College of Physicians of Canada (FRCPC)

AUG 2022 - GMC Full Registration with License to Practise

SEPT 2022 - Royal College of Canada Speciality Examination Medical Oncology

SEPT 2020 - Royal College of Canada Speciality Examination Internal Medicine

OCT 2018 - Licentiate of the Medical Council of Canada (LMCC)

• **Professional Organizations:**

JAN 2023 - European Society for Medical Oncology (ESMO) Clinical Practice Guidelines Member -  
Renal Cell Carcinoma

NOV 2022 - Senior doctor in clinical trial delivery group - Barts Cancer Institute

JUN 2021-2022 Chief Resident Medical Oncology - McGill University

**• Main Scientific Publications:**

AUG2024 - The Lancet Young, M., Jackson-Spence, F., Beltran, L., Day, E., Suarez, C., Bex, A., ... & Szabados, B. (2024). Renal cell carcinoma. The Lancet, 404(10451), 476-491. Annals of Oncology Powles, T., Albiges, L., Bex, A., Comperat, E., Grünwald, V., Kanesvaran, R., ... Young, M. & Gillessen, S. (2024). Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology.

JUN 2024 - Clinical Genitourinary Oncology Young, M., Tapia, J. C., Szabados, B., Jovaisaite, A., Jackson-Spence, F., Nally, E., & Powles, T. (2024). NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer, 22(3), 102072.

MAY 2024 - Cancer Management and Research Nally, E., Young, M., Chauhan, V., Wells, C., Szabados, B., Powles, T., & Jackson-Spence, F. (2024). Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge. Cancer Management and Research, 467-475

Urologic Oncology Jackson-Spence, F., Ackerman, C., Jones, R., Toms, C., Jovaisaite, A., Young, M., ... & Szabados, B. (2024, November). Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel. Urologic Oncology: Seminars and Original Investigations (Vol. 42, No. 11, pp. 372-e1). Elsevier.

MARCH 2024 - European Urology Focus Young, M. (2024). The Future of Front-line Metastatic Bladder Cancer is Platinum-free. European Urology Focus, 10(2), 215-216. Nally, E., Young, M., Wells, C., Fairhead, R., Baines, K., Cheney-Lowe, H., ... & Powles, T. (2024). Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?. European Urology Focus.

JAN 2024 - Canadian Medical Association Journal Chen, Y., MacIsaac, S., Young, M. & Khan, F. (2024). Nunavimmi puvakktut kaggutimik aanniaqarniq: Qanuilirqitaa? Lung cancer in Nunavik: How are we doing? A retrospective matched cohort study. CMAJ.

Kidney Cancer Jackson-Spence, F., Young, M., Jovaisaite, A., Szabados, B., & Powles, T. (2024). Adjuvant Therapy in Renal Cell Cancer. Kidney Cancer, 8(1), 17-22.